Get the Stockscreener App
16.23
6.46%
-1.12
After Hours:
16.33
0.10
+0.62%
Definium Therapeutics Inc stock is traded at $16.23, with a volume of 1.28M.
It is down -6.46% in the last 24 hours and up +0.00% over the past month.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).
See More
Previous Close:
$17.35
Open:
$17.35
24h Volume:
1.28M
Relative Volume:
2.52
Market Cap:
$1.60B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.12%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$16.18
$17.54
1-Week Range:
$16.18
$17.80
52-Week Range:
$14.62
$18.70
Definium Therapeutics Inc Stock (DFTX) Company Profile
Name
Definium Therapeutics Inc
Sector
Industry
Phone
212-220-6633
Address
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
16.23 | 1.71B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | Jefferies | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Aug-04-25 | Resumed | Oppenheimer | Outperform |
| Jan-28-25 | Initiated | Evercore ISI | Outperform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Jul-24-24 | Initiated | ROTH MKM | Buy |
| May-29-24 | Initiated | Robert W. Baird | Outperform |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | Canaccord Genuity | Buy |
| Dec-09-22 | Resumed | ROTH Capital | Buy |
| Nov-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-26-22 | Initiated | Oppenheimer | Outperform |
| Aug-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-04-22 | Initiated | ROTH Capital | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
View All
Definium Therapeutics Inc Stock (DFTX) Latest News
Is Adsett’s Board Appointment And Breakthrough DT120 Status Altering The Investment Case For Definium Therapeutics (DFTX)? - simplywall.st
Pharma Co. Stole Secrets For LSD Medical Trials, Suit Says - Law360
Definium Therapeutics Announces New Employee Inducement GrantsFebruary 3, 2026 - BioSpace
Definium Therapeutics stock hits 52-week high at 18.19 USD By Investing.com - Investing.com Nigeria
LSD therapy biotech Definium sued for alleged trade secret theft | Business Information & News | FE - Westlaw Today
LSD therapy biotech Definium sued for alleged trade secret theft - Reuters
Company Researching LSD Applications Faces Trade Secrets Litigation in Delaware Federal Court - Law.com
Definium Therapeutics (NASDAQ:DFTX) Hits New 52-Week HighShould You Buy? - MarketBeat
Definium Therapeutics stock hits 52-week high at 18.19 USD - Investing.com
Cantor Fitzgerald reiterates Overweight rating on Definium stock By Investing.com - Investing.com UK
Cantor Fitzgerald reiterates Overweight rating on Definium stock - Investing.com
Definium Therapeutics (NASDAQ:DFTX) Research Coverage Started at Jefferies Financial Group - Defense World
Did Adding Biopharma Veteran Roger Adsett to the Board Just Shift Definium Therapeutics' (DFTX) Investment Narrative? - Yahoo Finance
Definium Therapeutics (NASDAQ:DFTX) Upgraded to Strong-Buy at Jefferies Financial Group - MarketBeat
Roger Adsett Joins Definium As Commercial Focus Meets Trial Milestones - Yahoo Finance
Definium Therapeutics Adds Commercial Leader As Phase 3 Milestones Approach - Sahm
Commit To Buy Definium Therapeutics At $10, Earn 21.9% Annualized Using Options - Nasdaq
Jefferies Initiates Coverage on Definium Therapeutics With Buy Rating, $30 Price Target - marketscreener.com
Jefferies initiates coverage on Definium Therapeutics stock with Buy rating - Investing.com India
Definium Therapeutics appoints Roger Adsett to board of directors By Investing.com - Investing.com Nigeria
Critical Contrast: Definium Therapeutics (NASDAQ:DFTX) vs. Tetra Bio-Pharma (OTCMKTS:TBPMF) - Defense World
Jefferies initiates coverage on Definium Therapeutics stock with Buy rating By Investing.com - Investing.com UK
Definium Therapeutics (DFTX) Expands Board with New Appointment - GuruFocus
Definium Therapeutics Appoints Roger Adsett To Board - citybiz
Definium Therapeutics Appoints Roger Adsett to Board of Directors, Effective from January 29, 2025 - marketscreener.com
Definium Therapeutics Expands Board, Appoints New Director - TipRanks
Definium Therapeutics appoints Roger Adsett to board of directors - Investing.com
Definium Therapeutics Appoints Roger Adsett to Board of Directors - Yahoo Finance
Will Definium's ‘Rerouting Minds’ LSD Education Push Recast DFTX’s Science-First Psychedelic Narrative? - simplywall.st
Certain Pre-funded warrants of Definium Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-JAN-2026. - marketscreener.com
Breakthrough or Bubble? The High-Stakes 2026 Readouts for Psychedelic Giants - geneonline.com
DFTX Stock Price and Chart — NASDAQ:DFTX - TradingView
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Definium Therapeutics (NASDAQ:DFTX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - Defense World
A Look At Definium Therapeutics (DFTX) Valuation After Rerouting Minds Campaign Highlights Psychedelic LSD Programs - simplywall.st
Definium Therapeutics (FRA:MMQ0) Momentum Rank : 2 (As of Jan. 24, 2026) - GuruFocus
DFTX: RBC Capital Raises Price Target for Definium Therapeutics - GuruFocus
Definium Therapeutics stock price target raised to $36 from $20 at RBC Capital - Investing.com India
RBC Raises Price Target on Definium Therapeutics to $36 From $20, Keeps Outperform, Speculative Risk - marketscreener.com
Definium Therapeutics (NASDAQ:DFTX) Sets New 52-Week HighHere's What Happened - MarketBeat
Deinium Therapeutics (DFTX) Is Up 11.5% After Psychedelic Rebrand And DT120 Roadmap Reveal Has The Bull Case Changed? - Sahm
Definium launches educational campaign on LSD for mental health By Investing.com - Investing.com South Africa
Definium Therapeutics Launches Educational LSD Campaign to Advance Psychedelic Psychiatry - TipRanks
Definium Therapeutics Inc Stock (DFTX) Financials Data
There is no financial data for Definium Therapeutics Inc (DFTX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):